转移性去势抵抗性前列腺癌患者接受177Lu-PSMA-617治疗中前列腺特异性抗原下降与临床结局的关联:3期VISION试验分析
该研究为3期VISION试验的事后分析,纳入551例接受177Lu-PSMA-617联合标准治疗的前列腺特异性膜抗原阳性转移性去势抵抗性前列腺癌患者。按第12周前未确认的前列腺特异性抗原下降幅度分组,下降≥0-<50%、≥50-<90%和≥90%的患者相较前列腺特异性抗原升高者,影像学进展或死亡风险分别降低61%、72%和88%,死亡风险分别降低51%、70%和87%。前列腺特异性抗原下降幅度越大,影像学缓解越频繁,健康相关生活质量和疼痛评分至恶化的中位时间越长。
要点
- 前列腺特异性抗原下降≥0-<50%、≥50-<90%和≥90%组相较升高组,影像学进展或死亡风险分别降低61%、72%和88%。
- 上述三组相较升高组,死亡风险分别降低51%、70%和87%。
- 前列腺特异性抗原下降幅度越大,影像学缓解越频繁,健康相关生活质量和疼痛评分至恶化的中位时间越长。
核心结论
- 在接受177Lu-PSMA-617联合标准治疗的转移性去势抵抗性前列腺癌患者中,前列腺特异性抗原下降幅度与临床及患者报告结局的改善相关,提示前列腺特异性抗原下降在该治疗期间似乎具有预后价值。
研究设计与样本
- 3期VISION试验的事后分析,纳入831例既往接受过一种或多种雄激素受体通路抑制剂和一到两种紫杉烷类治疗的PSMA阳性进展性转移性去势抵抗性前列腺癌患者,其中551例随机分配至177Lu-PSMA-617联合方案允许的标准治疗组。
主要发现
- 截至第12周(含第12周),最佳前列腺特异性抗原下降≥0-<50%组96/551例(17%)、≥50-<90%组152/551例(28%)、≥90%组83/551例(15%),相较前列腺特异性抗原升高组160/551例(29%),影像学疾病进展或死亡风险分别降低61%、72%和88%,死亡风险分别降低51%、70%和87%(基于多变量Cox比例风险模型的风险比)。
- 前列腺特异性抗原下降幅度更大的患者中,影像学缓解更频繁,健康相关生活质量和疼痛评分至恶化的中位时间更长。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The prognostic value of declining prostate-specific antigen (PSA) levels is under investigation in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) receiving PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-617 (177Lu-PSMA-617). This post hoc analysis of the phase 3 VISION trial aimed to evaluate associations between PSA decline and clinical and patient-reported outcomes in patients receiving 177Lu-PSMA-617. METHODS: Of 831 enrolled patients with PSMA-positive progressive mCRPC treated previously with one or more androgen receptor pathway inhibitors and one to two taxanes, 551 were randomised to 177Lu-PSMA-617 plus protocol-permitted standard of care (SoC). Radiographic progression-free survival, overall survival, radiographic objective response rate, and patient-reported health-related quality of life (HRQoL) and pain were analysed in subgroups of patients categorised by the magnitude of unconfirmed PSA decline from baseline. KEY FINDINGS AND LIMITATIONS: Patients randomised to 177Lu-PSMA-617 with the best PSA declines of ≥0-<50% (96/551 [17%]), ≥50-<90% (152/551 [28%]), and ≥90% (83/551 [15%]) up to and including week 12 had 61%, 72%, and 88% reduced risks of radiographic disease progression or death, and 51%, 70%, and 87% reduced risks of death, respectively, versus those with increased PSA levels (160/551 [29%]), based on hazard ratios in a multivariate Cox proportional hazard model. In patients with greater PSA declines, radiographic responses were more frequent and median time to worsening in HRQoL and pain scores were longer. CONCLUSIONS AND CLINICAL IMPLICATIONS: The magnitude of PSA decline was associated with improvement in clinical and patient-reported outcomes in patients with mCRPC receiving 177Lu-PSMA-617 plus SoC in VISION. PSA decline therefore appears to have a prognostic value during 177Lu-PSMA-617 treatment in this population.
引用
- Armstrong AJ, Sartor O, de Bono J, et al. Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial. Eur Urol. 2024. PMID: 39242323. doi:10.1016/j.eururo.2024.08.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。